RxDoctor Payments Data

Emmanuel Yumang, MD

Geriatric Medicine · London, KYNPI 1730135138

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,252 and has fallen 87.3% since, to $159 in 2025.

$1,933in general payments, 2019–2025

Across 143 payments — averaging $13.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$339
  • Pfizer$262
  • Merck$134
  • Takeda Pharmaceuticals U.S.A., Inc.$121
  • Boehringer Ingelheim$112
  • AbbVie$112
  • plus $854 from 14 others

What the payments were for

  • Food & beverage$1,927100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,933 in reported general payments places this provider in the 80th percentile of 33 geriatric medicine providers in Kentucky.

See all geriatric medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$72,479
Medicare patients
239
Services billed
740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$35,192
OzempicSemaglutide13$12,426
MyrbetriqMirabegron72$8,163
JardianceEmpagliflozin11$7,617
FarxigaDapagliflozin Propanediol11$6,646
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,206
Divalproex Sodium39$1,063
Pantoprazole Sodium87$1,025
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc33$942
Atorvastatin Calcium99$544
Potassium Chloride66$490
Cefdinir67$406
Levothyroxine Sodium54$399
Mirtazapine80$352
Metoprolol Tartrate75$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$262$35,192106 claims
Novo NordiskOzempic$72$12,42613 claims
Boehringer IngelheimJardiance$112$7,61711 claims
AstraZenecaFarxiga$339$6,64611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 geriatric medicine providers in Kentucky.

Other geriatric medicine in London

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →